Infectious Diseases Catalyst Grants
Catalytic grants support innovative research on antimicrobial resistance or pandemic influenza, aiming for breakthroughs in prevention, diagnosis, or treatment of global infectious diseases.
Funder: Novo Nordisk Foundation
Due Dates (Anticipated): May 2027
Funding Amounts: Up to DKK 4 million per grant (single Nordic PI); up to DKK 7 million (Nordic PI + international co-applicant); project duration up to 3 years.
Summary: Catalytic funding for innovative research addressing antimicrobial resistance or pandemic influenza with high potential to impact global human infectious disease challenges.
Key Information: Main applicant must be employed at a Nordic non-profit research institution with ≥75% employment.
Description
This program provides catalytic funding for exploratory, use-inspired, and innovative research projects with exceptional potential to directly impact global challenges in human infectious diseases. Projects must address one of two themes: (1) developing novel tools to combat antimicrobial resistance (AMR), or (2) addressing major research gaps in pandemic influenza, including viral infectivity, transmission, and disease severity in humans. Supported projects should enhance fundamental knowledge while considering applications or translation of findings toward improved prevention, diagnosis, or treatment of infectious diseases. The program aims to catalyze research that could lead to significant future impacts beyond the scope of the funded project.
